| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Guangdong Jiaying Pharmaceutical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.00 |
| 52 Week High | CN¥9.15 |
| 52 Week Low | CN¥4.67 |
| Beta | 0.71 |
| 1 Month Change | 6.87% |
| 3 Month Change | 14.94% |
| 1 Year Change | -6.42% |
| 3 Year Change | -11.17% |
| 5 Year Change | 2.64% |
| Change since IPO | 59.09% |
Recent News & Updates
Shareholder Returns
| 2198 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 12.0% | -2.9% | -1.8% |
| 1Y | -6.4% | -14.7% | -13.0% |
Return vs Industry: 002198 exceeded the CN Pharmaceuticals industry which returned -14.7% over the past year.
Return vs Market: 002198 exceeded the CN Market which returned -13% over the past year.
Price Volatility
| 2198 volatility | |
|---|---|
| 2198 Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 002198 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002198's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 700 | n/a | www.gdjyzy.com.cn |
Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese patient medicines in Mainland China. The company offers medicines primarily for the treatment of throat, cold, orthopedics, rheumatism, gynecology, heat-clearing, tonic, and gastrointestinal diseases. It also offers provides Shuangliao Houfeng powder, Chongganling tablets, Jiegu Qili tablets (capsules), Shufenghuoluo tablets, Tiaomenghuoxue tablets, and etc. Guangdong Jiaying Pharmaceutical Co., Ltd.
Guangdong Jiaying Pharmaceutical Co., Ltd Fundamentals Summary
| 2198 fundamental statistics | |
|---|---|
| Market cap | CN¥3.55b |
| Earnings (TTM) | CN¥27.32m |
| Revenue (TTM) | CN¥499.15m |
130.1x
P/E Ratio7.1x
P/S RatioIs 2198 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2198 income statement (TTM) | |
|---|---|
| Revenue | CN¥499.15m |
| Cost of Revenue | CN¥185.37m |
| Gross Profit | CN¥313.79m |
| Other Expenses | CN¥286.47m |
| Earnings | CN¥27.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.054 |
| Gross Margin | 62.86% |
| Net Profit Margin | 5.47% |
| Debt/Equity Ratio | 0% |
How did 2198 perform over the long term?
See historical performance and comparison